This page shows what was measured, who it was measured in, and what that does not settle.
What Capsaicin does in the body
QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet.
From the FDA-approved label: Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), which is an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Topical administration of capsaicin causes an initial enhanced stimulation of the TRPV1-expressing cutaneous nociceptors that may be associated with painful sensations. 2 )] . Over the course of several months, there may be a gradual re-emergence of painful neuropathy thought to be due to TRPV1 nerve fiber reinnervation of the treated area.
Why people take it. QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · S07O44R1ZM · read 2026-08-29
The supplement label database classes it as non-nutrient/non-botanical, under the name Capsaisin.
Its recorded molecular formula is C18H27NO3, weighing 305.42.
US prescribing information · 3ffbbcb0-ad93-4f15-bb38-5da76a71c735 · read 2026-08-30
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 150 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Pain
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
…Waiting for a reviewer10 registered symptom measure.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Mood
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Energy
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Strength
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
…Waiting for a reviewer1 registered performance measure of this kind.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Endurance
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
…Waiting for a reviewer1 registered performance measure of this kind.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Pain
frequency of mouth pain; duration of mouth pain; severity of mouth pain; pain report during labor; pain relief from pain reduction using visual analog scale; pain scores on the visual analogue scale; pain on a visual analogue scale; average pain nprs scores
Mood
time to onset of 1mm st segment depression; maximal st depression
Energy
energy substrate use
Strength
iopi will be used to measure lingual strength and endurance
Endurance
iopi will be used to measure lingual strength and endurance
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
… Waiting for a reviewer
10 registered symptom measure.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Brief Pain Inventory (BPI) Interference scale
✗ The study did not show it
Who was studied
NCT04142177
How many people
2529
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
Number of Participants With Treatment Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)
✗ The study did not show it
Who was studied
NCT00809783
How many people
2147
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
Determination of Optimal Procedure for Administering CNTX-4975-05 With Regards to Pain, Participant Satisfaction, and Investigator's Satisfaction
✗ The study did not show it
Who was studied
NCT03661996
How many people
854
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
✗ The study did not show it
Who was studied
NCT00924664
How many people
849
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
Incidence of PHN
✗ The study did not show it
Who was studied
NCT07361796
How many people
832
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
Change in POM Between Baseline and Day 2 Evening, 1 Hour After Drug Application
✗ The study did not show it
Who was studied
NCT02700815
How many people
746
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Topical
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
□Living longer, or avoiding a major eventNo evidence recorded. Death, a heart attack, a stroke, a hospital stay.No registered study measures this.
■What a body can do day to dayEvidence recorded. Walking, dressing, breathing, recovering.1 registered measure of this kind.
■Measured performanceEvidence recorded. How much was lifted, how far was run, how fast.1 registered measure of this kind.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.11 registered measures of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.2 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Drosophila (fruit fly), Mouse, Rat. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
frequency of mouth pain
duration of mouth pain
severity of mouth pain
pain report during labor
pain relief from pain reduction using visual analog scale
pain scores on the visual analogue scale
pain on a visual analogue scale
average pain nprs scores
neuropathic pain
total symptom
and 1 more.
Measured
Things only a test, a scale or a device shows.
iopi will be used to measure lingual strength and endurance
plasma calcitonin gene related peptide levels
inflammatory cytokines profile
Meaningful
Things that change how a life goes, not only a number.
No registered study measured anything of this kind.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (26)
amplitude of the vasomotor response to stimuli
hyperalgesia
visual analogue scale
neuro immunological effect
time to onset of 1mm st segment depression
time to onset of angina or angina equivalent symptoms
maximal st depression
maximal estimated workload
severity of angina was measured
adverse events
serious adverse events
treatment emergent adverse events
safety measures
time to retreatment
lung volume initiation
negative mucosa potentials
maximum expiratory pressure
neuroimaging changes of salty gustatory cortices
performance
energy substrate use
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
When using this product do not apply to wounds, broken or irritated skin Luse only as directed I avoid contact with eyes ora burning, stinging or warming sensation may occur upon application and generallymucous membraneslessens with continued use; if severe burning occurs, discontinue use do not bandage tightly do notuse with a heating pad or right after bathing /shower do not expose the treated area to heat or…
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of QUTENZA in patients younger than 18 years of age have not been studied.”
US prescribing information · 3ffbbcb0-ad93-4f15-bb38-5da76a71c735 · read 2026-08-30
On older people, the label states: “In controlled clinical trials of QUTENZA in neuropathic pain associated with postherpetic neuralgia, 75% of patients were 65 years and older and 43% of patients were 75 years and older.”
US prescribing information · 3ffbbcb0-ad93-4f15-bb38-5da76a71c735 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Capsaicin is negligibly absorbed systemically following topical administration of QUTENZA, and maternal use is not expected to result in the fetal exposure to QUTENZA.”
US prescribing information · 3ffbbcb0-ad93-4f15-bb38-5da76a71c735 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary Capsaicin is negligibly absorbed systemically by the mother following topical administration of QUTENZA, and breastfeeding is not expected to result in exposure of the infant to QUTENZA [see Clinical Pharmacology ( 12.3 )] .”
US prescribing information · 3ffbbcb0-ad93-4f15-bb38-5da76a71c735 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Topical
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as patch, cloth, gel, cream, given by the topical, transdermal, cutaneous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Capsaicin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 424 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
application site pain — 114 reaction mentions
application site erythema — 65 reaction mentions
pain — 48 reaction mentions
drug hypersensitivity — 32 reaction mentions
application site burn — 28 reaction mentions
burning sensation — 28 reaction mentions
occupational exposure to product — 28 reaction mentions
application site vesicles — 27 reaction mentions
erythema — 27 reaction mentions
insomnia — 27 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Topical
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
211 products list this as an active ingredient in the United States drug directory. 129 of them contain it and nothing else.
FDA National Drug Code directory · 71574-600 · read 2026-08-29
They are sold as cloth, cream, gel, liniment, liquid and lotion, taken cutaneous, topical and transdermal.
FDA National Drug Code directory · 71574-600 · read 2026-08-29
209 published labels name it as an active ingredient. 128 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 49eb807b-fa31-3d84-e063-6394a90acfcf · read 2026-08-29
Those labels are classed as human otc drug and human prescription drug.
US prescribing information · 49eb807b-fa31-3d84-e063-6394a90acfcf · read 2026-08-29
1366 marketed supplement labels list this ingredient, classed as botanical and other combinations.
Those labels carry all other, nutrient and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
Recorded price in US: 0.06969–0.20178 USD per one gram, across 6 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Recorded price in US: 1.11677 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, for the one priced product, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Capsaicin studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How fast does the body clear it?
The sources RNAWiki checked hold nothing for this field.
Why it matters. Without this, nothing on this page can say how long anything lasts.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Capsaicin are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
S07O44R1ZM
CAS registry number
404-86-4
PubChem compound
1548943
ChEMBL
CHEMBL294199
ChEBI
3374
WHO international nonproprietary name list entry
10145
RxNorm concept
1992
EMA substance identifier
100000076831
European Chemicals Agency number
206-969-8
DrugBank
DB06774
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
1 approved application covers products containing this substance. The earliest was NDA022395, approved 20091116 to AVERITAS.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q1
What did Capsaicin's largest trial (854 people) and its longest (13 years) measure?
854 people in Capsaicin's largest registered study, 13 years in its longest registered window, measuring C5 (Provocant concentration eliciting at least 5 coughs). ClinicalTrials.gov · 2026-09-01
27 phase2, 22 na, 20 phase3, 17 phase4, 15 phase1, 14 na or unstated, 8 early phase1; NCT00001307; 2005-08. Last human test completed 2026, NCT07598994.
Interpretation These counts include studies where Capsaicin was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
27
na
22
phase3
20
phase4
17
phase1
15
na or unstated
14
2 more recorded rows
early phase1
8
Last recorded human testNCT07598994
2026-04-06
recorded 2026-09-01 · last checked 2026-09-04
Q2
From Drosophila to human: where has Capsaicin shown lifespan?
20 recorded entries; human; patch, topical; also "the brandname of NGX-4010, 8% capsaicin patch is Qutenza.", "0.04% capsaicin patch", "The brandname of NGX-4010, 8% capsaicin patch is Qutenza."
Show the evidence
human
NCT00321672
patch; NGX-4010, 8% capsaicin patch
NCT00321672
patch; the brandname of NGX-4010, 8% capsaicin patch is Qutenza.
NCT00321672
patch; 0.04% capsaicin patch
NCT00321672
patch; The brandname of NGX-4010, 8% capsaicin patch is Qutenza.
NCT00655811
Topical capsaicin, 0.1%, Capzasin HP
NCT01231750
capsaicin cream 0.1%, generic
14 more recorded rows
humanNCT01260454
Qutenza (8% capsaicin)
humanNCT01416116
patch; capsaicin 8% patch
humanNCT01533428
Capsaicin 8%
humanNCT01704339
Topical capsaicin 8%
humanNCT01748435
topical; Qutenza (topical capsaicin 8%)
humanNCT02403687
Capsaicin, USP 0.0375%
humanNCT02441660
Capsaicin 8% Patch
humanNCT02441660
Low Dose Capsaicin 0.025% Well Patch
humanNCT03317613
patch; 8% capsaicin patch
humanNCT03464292
Capsaicin Patch 8% or 0.1% Capsaicin Cream
humanNCT04238208
Capsaicin 8% Patch, Per 10 Square Centimeters
humanNCT04361149
Capsaicin Topical Cream (0.075%)
humanNCT05649228
Capsaicin 0.1% Cream
humanNCT05649228
Capsaicin Palmitate 0.25% Cream
recorded 2026-09-01 · last checked 2026-09-04
Q5
More Capsaicin was worse in human: at what point?
Hormetic in human: "Furthermore, the lifespan-extending effects of capsaicin were concentration-dependent, suggesting potential hormetic mechanisms." Europe PMC · dose-response search · 2025-10-01
5 recorded sentences naming Capsaicin; hormetic, biphasic, Dose-response, dose-response
Show the evidence
hormetic
"Furthermore, the lifespan-extending effects of capsaicin were concentration-dependent, suggesting potential hormetic mechanisms."
biphasic
PMID 40540176
"Nicorandil (150 mg/kg, twice, 2 h apart, PO) administered to male rats (i) reversed the effects of CCI on nociceptive threshold and cumulative scores assessed by von Frey and acetone test, respectively; (ii) reduced licking time and number of flinches in biphasic formalin and capsaicin tests, and (iii) reduced the number of writhes in the acetic acid test; and (iv) combined nicorandil-capsaicin…"
PMID 37783858
"The in vitro release studies showed a biphasic release profile for capsaicin, and the release was sustained for more than three months (~ 85% released) irrespective of drug loading and infill densities."
Dose-responsePMID 36736541
"Dose-response capsaicin cough challenges were performed, and receiver operating characteristic curves constructed to evaluate the discriminatory value of novel endpoints; Emax (maximum number of coughs evoked by any capsaicin concentration) and ED50 (capsaicin concentration evoking at least half of Emax)."
dose-responsePMID 36736541
"Novel capsaicin dose-response endpoints effectively discriminate between healthy controls and refractory chronic cough patients, which may better represent pathophysiological mechanisms and show promise for development as a tool to identify patients with cough hyper-excitability."
recorded 2025-10-01 · last checked 2026-09-04
Q6
Could one person measure Capsaicin's effect on frequency of mouth pain?
Frequency of mouth pain: measured in Capsaicin's trials.
Interpretation frequency of mouth pain is the recorded endpoint.
Show the evidence
biomarkers
frequency of mouth pain; 2026-09-01
duration of mouth pain; 2026-09-01
severity of mouth pain; 2026-09-01
amplitude of the vasomotor response to stimuli; 2026-09-01
hyperalgesia; 2026-09-01
pain report during labor; 2026-09-01
14 more recorded rows
biomarkers
visual analogue scale; 2026-09-01
biomarkers
pain relief from pain reduction using visual analog scale; 2026-09-01
biomarkers
pain scores on the visual analogue scale; 2026-09-01
biomarkers
neuro immunological effect; 2026-09-01
biomarkers
time to onset of 1mm st segment depression; 2026-09-01
biomarkers
time to onset of angina or angina equivalent symptoms; 2026-09-01
biomarkers
maximal st depression; 2026-09-01
biomarkers
maximal estimated workload; 2026-09-01
biomarkers
severity of angina was measured; 2026-09-01
biomarkers
adverse events; 2026-09-01
biomarkers
serious adverse events; 2026-09-01
biomarkers
treatment emergent adverse events; 2026-09-01
biomarkers
pain on a visual analogue scale; 2026-09-01
biomarkers
safety measures; 2026-09-01
human trials at or under30
43
Not recorded for this substance
a recorded half-life
smallest human trial
0; NCT00771511; PHASE4; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q7
Which of activation of the nucleus of the solitary tract, adverse events and amplitude of the vasomotor response to stimuli did Capsaicin's trials measure?
activation of the nucleus of the solitary tract, adverse events and amplitude of the vasomotor response to stimuli lead 40 outcome terms across Capsaicin's trials. ClinicalTrials.gov · 2026-09-01
Interpretation amplitude of the vasomotor response to stimuli, hyperalgesia, pain report during labor, visual analogue scale, pain relief from pain reduction using visual analog scale and pain scores on the visual analogue scale follow.
Show the evidence
frequency of mouth pain
1
duration of mouth pain
1
severity of mouth pain
1
amplitude of the vasomotor response to stimuli
1
hyperalgesia
1
pain report during labor
1
14 more recorded rows
visual analogue scale
1
pain relief from pain reduction using visual analog scale
1
pain scores on the visual analogue scale
1
neuro immunological effect
1
time to onset of 1mm st segment depression
1
time to onset of angina or angina equivalent symptoms
1
maximal st depression
1
maximal estimated workload
1
severity of angina was measured
1
adverse events
1
serious adverse events
1
treatment emergent adverse events
1
pain on a visual analogue scale
1
safety measures
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Capsaicin's 12 ongoing trials reports first?
Activation of trigeminoautonomic reflex as assessed by change in Calcitonin gene-related peptide (CGRP) levels from before stimulation to after stimulation.; The primary objective is to demonstrate that capsaicin 179 mg patch once compared to duloxetine daily, improves painful CIPN after a 5-week treatment period.; latest 2029-12
Show the evidence
Trial
NCT03511846
"Pain Biomarker Study"; n 371; "Activation of trigeminoautonomic reflex as assessed by change in Calcitonin gene-related peptide (CGRP) levels from before stimulation to after stimulation."; 2028-05-31
NCT05840562
"Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy"; n 274; "The primary objective is to demonstrate that capsaicin 179 mg patch once compared to duloxetine daily, improves painful CIPN after a 5-week treatment period."; 2028-03
NCT05983263
"Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA®) in Coccygodygnia"; n 106; "Responder rate"; 2027-06-08
NCT05997979
"Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children"; n 46; "The change in Neuropathic Pain Symptom Inventory score (NPSI)"; 2028-07-05
NCT06023706
"Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia."; n 188; "to demonstrate the analgesic effect at day 60 of 8% capsaicin patch (Qutenza) for the treatment of patients with coccygodyinia."; 2027-06-08
NCT06444594
"Transient Receptor Potential Channels"; n 45; "Skin blood flow during slow local heating"; 2027-12-31
6 further recorded trials
NCT06444919
"Capsaicin in Digital Osteoarthritis Versus Control"; n 120; "Intensity of pain in the fingers"; 2028-01-01
NCT06612658
"Acute Effect of Capsimax on Resistance Exercise Performance, Muscle Oxygenation, Nitric Oxide Release, Resting Energy Expenditure and Reaction Time"; n 40; "Resistance exercise performance"; 2025-05-30
NCT06807164
"Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome"; n 123; "Pain assessment using Numerical Pain Scale (END)"; 2027-12-30
NCT07237022
"The Role of TRP Channels in DPN"; n 20; "Dermal Blood Flow response (PU)"; 2026-08-31
NCT07238465
"Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome"; n 200; "Seated Baseline Concentration of Plasma Catecholamines"; 2029-12
NCT07260656
"Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain"; n 80; "Significant reduction in foot pain in participants with chronic diabetic neuropathic foot pain."; 2027-11
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which 57 trials of Capsaicin posted no result?
Posted no result
57 of 57 completed trials
Registrations
NCT00176969, NCT00034710, NCT00008476, NCT00001307, NCT00088686 and NCT00130949, and 51 more
Completion dates
oldest 2000-06; newest 2024-01-11
Show the evidence
Trial
NCT00176969
2000-06
NCT00034710
2002-10
NCT00008476
2004-01
NCT00001307
2005-08
NCT00088686
2005-10
NCT00130949
2005-11
14 further recorded trials
NCT00132392
2005-12
NCT00133133
2005-12
NCT00130962
2006-02
NCT00146198
2006-02
NCT00254449
2006-05
NCT00003610
2006-07
NCT00115310
2006-10
NCT00004316
2007-08
NCT00300222
2007-08
NCT00583180
2008-01
NCT00152724
2008-11
NCT01223820
2011-09
NCT00993070
2011-12
NCT01667523
2011-12
Q10
At the median, Capsaicin's trials enrolled 43 people — anything larger?
Median enrolment
43
Largest enrolment
854
Registered trials counted
114
Q11
What do 424 spontaneous reports say about Capsaicin — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Capsaicin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 424 reaction mentions were counted: application site pain 114; application site erythema 65; pain 48; drug hypersensitivity 32. open-targets-adr · CHEMBL294199 · 2026-06-24
Show the evidence
application site pain
114
application site erythema
65
pain
48
drug hypersensitivity
32
application site burn
28
burning sensation
28
4 more recorded rows
occupational exposure to product
28
application site vesicles
27
erythema
27
insomnia
27
recorded 2026-06-24 · last checked 2026-09-04
Q12
Capsaicin and cytochrome P450: shared by which compounds?
cytochrome P450 appear in Capsaicin's recorded interaction sentences, 1 in all. openfda-label+europepmc · 2026-07-07
Interpretation drug_interactions
Show the evidence
cytochrome P450drug_interactions
Data from in vitro cytochrome P450 inhibition and induction studies show that capsaicin does not inhibit or induce liver cytochrome P450 enzymes at concentrations which far exceed those measured in blood samples.
recorded 2026-07-07 · last checked 2026-09-04
Q13
Was Capsaicin studied with fasting and exercise?
fasting and exercise are named in Capsaicin's label sentences: "Compared to the placebo group, 2-h PG and 2-h INS concentrations and 2-h postprandial HOMA-IR (2-h HOMA-IR) levels, and the fasting serum total cholesterol and triglycerides concentrations significantly decreased in the capsaicin group after treatment (P < 0.05)." openfda-label+europepmc · 2026-07-07
2 recorded statements; fasting, exercise
Show the evidence
fasting
Compared to the placebo group, 2-h PG and 2-h INS concentrations and 2-h postprandial HOMA-IR (2-h HOMA-IR) levels, and the fasting serum total cholesterol and triglycerides concentrations significantly decreased in the capsaicin group after treatment (P < 0.05).
exercise
For subsequent resistance exercise, there was a significant decrease in volume across time (F = 19.889, p < 0.001, η2= 0.69) with maximal number of repetitions performed in capsaicin than placebo condition (2,077.6 ± 465.2 kg vs. 1,838.9 ± 624.1 kg, p = 0.028, d = 0.43), but the condition vs. set was not significant (F = 0.582, p = 0.632, η2= 0.06).
recorded 2026-07-07 · last checked 2026-09-04
Q14
What is recorded about Capsaicin and AMPK?
"Capsaicin's effectiveness in alleviating the bone-damaging effect of dexamethasone was evident through a dose-dependent reduction in ALP, RANKL, and Bax, a rise in osteocalcin and Bcl-2, and a higher expression of AMPK, SIRT1, β-catenin, and RUNX2." — where Capsaicin and AMPK appear together. Europe PMC · pathway abstract search · 2026-04-01
"Capsaicin's effectiveness in alleviating the bone-damaging effect of dexamethasone was evident through a dose-dependent reduction in ALP, RANKL, and Bax, a rise in osteocalcin and Bcl-2, and a higher expression of AMPK, SIRT1, β-catenin, and RUNX2."
sirtuinPMID 40425907
"Capsaicin's effectiveness in alleviating the bone-damaging effect of dexamethasone was evident through a dose-dependent reduction in ALP, RANKL, and Bax, a rise in osteocalcin and Bcl-2, and a higher expression of AMPK, SIRT1, β-catenin, and RUNX2."
AMPKPMID 40425907
"By upregulating the AMPK/SIRT1/β-catenin/RUNX2 pathway, capsaicin exhibits dose-dependent bone-stimulant effects in a dexamethasone-induced osteoporosis model in rats."
sirtuinPMID 40425907
"By upregulating the AMPK/SIRT1/β-catenin/RUNX2 pathway, capsaicin exhibits dose-dependent bone-stimulant effects in a dexamethasone-induced osteoporosis model in rats."
mTORPMID 40956702
"More importantly, capsaicin increased Ca2+ influx and autophagy and inhibited phosphorylation of the PI3K/AKT/mTOR signaling pathway."
autophagyPMID 40956702
"More importantly, capsaicin increased Ca2+ influx and autophagy and inhibited phosphorylation of the PI3K/AKT/mTOR signaling pathway."
6 more recorded rows
mTORPMID 40956702
"In conclusion, capsaicin protects BMSC function during oxidative stress, possibly through inducing TRPV1-mediated Ca2+ influx and PI3K/AKT/mTOR-activated autophagy."
autophagyPMID 40956702
"In conclusion, capsaicin protects BMSC function during oxidative stress, possibly through inducing TRPV1-mediated Ca2+ influx and PI3K/AKT/mTOR-activated autophagy."
IGF-1PMID 41987603
"Furthermore, capsaicin treatment downregulated IGF-1 expression, suggesting its potential role in modulating IGF-1 signalling involved in cellular proliferation and differentiation and reversing prostate hyperplasia."
mTORPMID 38706122
"Notably, AMPK knockdown abolished the inhibitory effects of capsaicin and cisplatin on the AKT/mTOR signaling pathway and Warburg effect."
AMPKPMID 38706122
"Notably, AMPK knockdown abolished the inhibitory effects of capsaicin and cisplatin on the AKT/mTOR signaling pathway and Warburg effect."
autophagyPMID 40719096
"Here, it is revealed that capsaicin ameliorated AD-related pathology by activating peroxisome proliferator-activated receptor alpha (PPARA/PPARα, a key regulator of lipid metabolism) to promote lipid metabolism and reverse autophagy-lysosomal deficits."
IGF-1
PMID 38919332
"Surprisingly, acute exposure to IGF-1 profoundly inhibited both the TRPV1 current and the spike burst evoked by capsaicin."
PMID 38919332
"The Src kinase inhibitor PP2 potently depressed the capsaicin-evoked spike burst but did not alter the IGF-1 inhibition of the hyperexcitability triggered by capsaicin."
sirtuinPMID 33163267
"Given that tNOX catalyzes the oxidation of NADH, the direct binding of capsaicin to tNOX also inhibited the NAD<sup>+</sup>-dependent activity of sirtuin 1 (SIRT1) deacetylase, we found that capsaicin-induced autophagy involved enhanced acetylation of ULK1, which is a key player in autophagy activation, possibly through SIRT1 inhibition."
NAD+
PMID 33163267
"Given that tNOX catalyzes the oxidation of NADH, the direct binding of capsaicin to tNOX also inhibited the NAD<sup>+</sup>-dependent activity of sirtuin 1 (SIRT1) deacetylase, we found that capsaicin-induced autophagy involved enhanced acetylation of ULK1, which is a key player in autophagy activation, possibly through SIRT1 inhibition."
PMID 34659883
"The inhibition of tNOX by capsaicin was accompanied by the attenuation of SIRT1, a NAD<sup>+</sup>-dependent deacetylase."
"The inhibition of tNOX by capsaicin is accompanied by the attenuation of SIRT1, a NAD<sup>+</sup>-dependent deacetylase that enhances ULK1 acetylation to induce ROS-dependent autophagy in melanoma cells."
recorded 2026-04-01 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.